Candid Therapeutics Enters into Agreement with WuXi Biologics on Trispecific T-cell Engager
SAN DIEGO & SHANGHAI–(BUSINESS WIRE)–Candid Therapeutics, Inc. (“Candid”), a clinical-stage biotechnology company focused on becoming the leader in advancing T-cell engagers for autoimmune and inflammatory diseases, announced today an agreement with WuXi Biologics under which Candid will have exclusive global rights to a preclinical trispecific T-cell Engager discovered at WuXi Biologics’ proprietary universal multispecific antibody […]
